Food Allergy Immunotherapy Market to Reach USD 249.3 Million by 2035, Driven by Growth Across APAC, Europe, USA & Saudi Arabia

The Food Allergy Immunotherapy Market is on track for strong double-digit growth across major regions, with global revenues forecasted to rise from USD 99.7 million in 2025 to USD 249.3 million by 2035, reflecting an 8.1% CAGR over the decade. The rapid adoption of immunotherapy protocols-led by PALFORZIA and XOLAIR-is redefining the management of food allergies, particularly in pediatric care.

Explore trends before investing - request a sample report today!
https://www.futuremarketinsights.com/reports/sample/rep-gb-22924

Europe and USA Lead Early Adoption; APAC Gains Traction

Europe and North America remain the epicenters of early adoption, with Europe expected to register a 9.1% CAGR and the United States maintaining 7.5% CAGR through 2035. Germany and the UK are at the forefront of Europe's immunotherapy ecosystem, benefiting from robust allergy care infrastructure and government-backed pediatric allergy programs.

In the United States, strong clinical validation of PALFORZIA and the recent FDA approval of XOLAIR® for multiple food allergies have solidified the country's leadership position. Pediatric allergy centers and academic institutions are increasingly integrating immunotherapy into mainstream treatment, backed by comprehensive insurance coverage and digital adherence programs.

Asia Pacific and Saudi Arabia: Emerging Hotspots for Growth

The Asia Pacific region, particularly India, China, Japan, and South Korea, is emerging as the next growth frontier. Rising food allergy prevalence among children, expanding healthcare access, and growing clinical trials for oral immunotherapy are reshaping treatment landscapes across the region.

• India is forecasted to grow at a 6.1% CAGR, driven by pediatric diagnosis and digital tele-allergy consultations.
• China is projected to expand at 6.0% CAGR, with research hubs in Beijing and Shanghai spearheading local OIT development.
• Japan is projected to reach USD 3.0 million by 2028, leveraging its structured school-based allergy screening system.
• South Korea, benefiting from government-led allergy surveillance and high digital health literacy, is predicted to record steady demand for OIT solutions.

In the Middle East, particularly Saudi Arabia, increasing adoption of advanced allergy care solutions and hospital-based desensitization programs positions the region as a key contributor to long-term market expansion. As healthcare modernization continues under Saudi Vision 2030, investment in chronic disease management-including pediatric allergies-is expected to accelerate market entry for leading immunotherapy products.

PALFORZIA Retains Market Leadership with 82.7% Share in 2025

PALFORZIA, developed by Stallergenes Greer, commands a dominant 82.7% market share in 2025. Its success stems from pioneering oral immunotherapy (OIT) solutions that provide clinically monitored exposure to allergens, helping desensitize patients and reduce the risk of severe reactions.

Meanwhile, XOLAIR, marketed by Genentech and Novartis, is rapidly emerging as a complementary biologic-based therapy, projected to hold a 22% market share by 2035. The introduction of combination therapies and biologic adjuncts reflects growing demand for safer and more flexible treatment options tailored to multiple allergen sensitivities.

Peanut Allergy Segment Dominates Immunotherapy Pipeline

Among allergen types, peanut allergy leads with 84.5% market share in 2025, representing the largest clinical and commercial opportunity. The prevalence of peanut-induced anaphylaxis, coupled with increased parental demand for proactive desensitization, continues to drive R&D investments. The success of PALFORZIA has validated peanut OIT's safety and efficacy, encouraging expansion into milk, egg, and multi-allergen desensitization protocols worldwide.

Technological Integration Reshapes Allergy Care

The market's evolution is increasingly defined by the integration of digital adherence tools, telehealth-based monitoring, and real-world data analytics. These technologies enable personalized dosing schedules and improve long-term treatment adherence. Clinics across the USA and Europe are adopting hybrid care models that combine in-person visits with remote progress tracking-enhancing safety, accessibility, and patient engagement.

Moreover, collaboration between biotech innovators and specialist allergy centers is fostering the use of AI-enabled data platforms to predict immunologic response, optimize up-dosing schedules, and ensure safety in pediatric desensitization.

Key Market Drivers and Outlook

Several factors underpin the market's continued growth:

• Rising prevalence of food allergies among children globally.
• Broader clinical acceptance of immunotherapy as a disease-modifying treatment.
• Expanding regulatory support and fast-track designations in the US and EU.
• Increasing integration of immunotherapy within national health systems.
• Growing parental awareness and willingness to invest in proactive allergy management.

As demand expands across both developed and emerging markets, the Food Allergy Immunotherapy Market is transitioning from niche to mainstream, propelled by precision medicine and digital transformation.

Buy Report Now - Click Here to Purchase the Report:
https://www.futuremarketinsights.com/checkout/22924

Latest Therapy Area Reports:-
Medical Eye Shield Film Market
https://www.futuremarketinsights.com/reports/medical-eye-shield-film-market

Medical Far Infrared Therapy Device Market
https://www.futuremarketinsights.com/reports/medical-far-infrared-therapy-device-market

Kids Splint Market
https://www.futuremarketinsights.com/reports/kids-splint-market

Why Choose FMI - Empowering Decisions that Drive Real-World Outcomes:
https://www.futuremarketinsights.com/why-fmi

Contact Us:

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware - 19713, USA
T: +1-347-918-3531
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com

LinkedIn| Twitter| Blogs | YouTube

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analystsworldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

This release was published on openPR.